e-learning
resources
Virtual 2021
06.09.2021
Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
In vitro discrimination between mesothelioma and lung cancer based on headspace volatile profiling
E. Janssens (Wilrijk, Belgium), Z. Mol (Ghent, Belgium), L. Vandermeersch (Ghent, Belgium), C. Walgraeve (Ghent, Belgium), J. Van Meerbeeck (Edegem, Belgium), E. Marcq (Wilrijk, Belgium), K. Lamote (Wilrijk, Belgium)
Source:
Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease
Session:
Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease
Session type:
Oral Presentation
Number:
1515
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Janssens (Wilrijk, Belgium), Z. Mol (Ghent, Belgium), L. Vandermeersch (Ghent, Belgium), C. Walgraeve (Ghent, Belgium), J. Van Meerbeeck (Edegem, Belgium), E. Marcq (Wilrijk, Belgium), K. Lamote (Wilrijk, Belgium). In vitro discrimination between mesothelioma and lung cancer based on headspace volatile profiling. 1515
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Refining the breath fingerprint of mesothelioma patients by in vitro identification of cancer cell line-specific volatile metabolites
Source: International Congress 2017 – Pleural and mediastinal malignancies
Year: 2017
A step towards easier diagnosis of lung cancer: Detection of volatile organic compounds in air releasing tumour samples with ion- and differential mobility spectrometry
Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Year: 2011
VOC analysis in headspace air of mesothelioma and lung cancer cell lines: A comparative literature study
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Novel non invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles.
Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies
Year: 2018
Volatile organic compounds (VOC) in non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Year: 2010
Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Gene expression profiling reveal novel biomarkers in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Volatile organic compounds in lung cancer patients before and after tumour resection
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Multi-omic molecular profiling of lung cancer in COPD
Source: Eur Respir J, 52 (1) 1702665; 10.1183/13993003.02665-2017
Year: 2018
Expression profiling in hypoxic non-small cell lung cancer explants reveals a four-gene hypoxia signature
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
Source: ERJ Open Res, 7 (1) 00787-2020; 10.1183/23120541.00787-2020
Year: 2021
PD-L1 determination in cytological and histological samples in patients with non-small cell lung cancer
Source: International Congress 2018 – Linear and radial EBUS and peripheral nodules
Year: 2018
Liquid biopsy for EGFR mutations in non-small cell lung cancer cases by RT-PCR
Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies
Year: 2018
Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages
Source: Eur Respir Rev, 29 (155) 190052; 10.1183/16000617.0052-2019
Year: 2020
Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
LSC Abstract – Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features
Source: International Congress 2016 – Lung cancer immunology: latest research
Year: 2016
Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept